J&J, AbbVie swell Imbruvica patient pool with FDA nod in CLL

AbbVie ($ABBV) has said it expects nearly a third of Imbruvica's future growth to come from moving into earlier lines of therapy in the drug's approved indications. And Friday, the therapy did just that, snagging a first-line go-ahead from the FDA in patients with chronic lymphocytic leukemia (CLL). More from FiercePharma

Read more on

Suggested Articles

A self-proclaimed former employee at Novartis’ Beijing office accused the Swiss drugmaker of expensing fake academic events to offer kickbacks to doctors.

Novo Nordisk just won an FDA approval that could help it stand out in the crowded—and competitive—basal insulin category.

Pfizer is training pharmacists in the U.K. to handle over-the-counter Viagra.